NIH-funded study finds personalized kidney screening for people with type 1 diabetes could reduce costs, detect disease earlier
NIH, November 2, 2022
Taking a personalized approach to kidney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected, according to a new analysis. According to the model’s findings: People with AER of 21-30 mg per 24 hours and a HbA1c of at least 9% are at high risk for developing CKD and could be screened for urine albumin every six months. This screening frequency could reduce time with undetected kidney disease so that appropriate interventions can be instituted as early as possible. Those with AER = 10 mg per 24 hours and a HbA1c = 8% are at lower risk for developing CKD and could be screened every two years. This change reduces patient burden and potentially saves millions of dollars compared to annual screening. All others with T1D = 5 years could continue to be screened annually.
Preeclampsia, Genomics and Public Health
E Dawson et al, CDC Blog Post, October 25, 2022
Preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies and is one of the leading causes of maternal morbidity. Risk factors for preeclampsia include first pregnancy; history of preeclampsia; history of hypertension, chronic kidney disease, or both; history of thrombophilia (a condition that increases risk of blood clots); pregnancy from in vitro fertilization; family history of preeclampsia. A recent study identified a cell free RNA (cfRNA) signature that was promising in predicting pre-eclampsia several weeks before the onset of symptoms.
Genome-wide polygenic score to predict chronic kidney disease across ancestries
A Khan et al, Nature Medicine, June 16, 2022
Chronic kidney disease (CKD) is a common complex condition associated with high morbidity and mortality. Polygenic prediction could enhance CKD screening and prevention; however, this approach has not been optimized for ancestrally diverse populations. By combining APOL1 risk genotypes with genome-wide association studies (GWAS) of kidney function, we designed, optimized and validated a genome-wide polygenic score (GPS) for CKD. The new GPS was tested in 15 independent cohorts, including 3 cohorts of European ancestry (n?=?97,050), 6 cohorts of African ancestry (n?=?14,544), 4 cohorts of Asian ancestry (n?=?8,625) and 2 admixed Latinx cohorts (n?=?3,625).
Chronic Kidney Disease Basics
CDC, March 2022
Kidney diseases are a leading cause of death in the United States. About 37 million US adults are estimated to have CKD, and most are undiagnosed. 40% of people with severely reduced kidney function (not on dialysis) are not aware of having CKD. Talk to your doctor about getting tested if you have any of these risk factors: Diabetes, High blood pressure, Heart disease, Family history of CKD, Obesity.